Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BICX104 PK and Safety Study in Healthy Volunteers
NCT07269873Phase 1Recruiting
- Sponsor
- BioCorRx Pharmaceuticals
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of naltrexone in substance use disorder (SUD) (4 arms), sponsored by BioCorRx Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at Day 196, Time to Maximum Plasma Concentration at Day 196 and 3 more. Started Mar 2026; status: recruiting.
02
Drugs
naltrexone
03
Conditions
substance use disorder (SUD)
Beyond the preview
Go deeper on NCT07269873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07269873.